{"entity":{"id":"nct06386146","kind":"trial","name":"JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","aka":[],"tldr":"A phase 1/2 trial of JAB-30355 in advanced solid tumours, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.","summary":"JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation is a phase 1/2 interventional study registered as NCT06386146 by Jacobio Pharmaceuticals Co., Ltd., with 144 participants planned, started 2024-07-24 and due to reach its primary completion in 2027-01. Interventions recorded: JAB-30355.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06386146","url":"https://clinicaltrials.gov/study/NCT06386146"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06386146","phase":"1/2","setting":"A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","enrolled":144,"outcomes":[]},"route":"/trials/nct06386146/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","route":"/companies/jacobio-pharmaceuticals/"}]}}